<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584074</url>
  </required_header>
  <id_info>
    <org_study_id>PreCox2</org_study_id>
    <nct_id>NCT03584074</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Pregabalin and COX2 in Spinal Stenosis</brief_title>
  <official_title>Comparative Study for Decrease of Pain Intensity and Pain Sensitivity Between Pregabalin + COX-2 Inhibitor and COX-2 Inhibitor in Patients With Lumbar Spinal Stenosis: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this prospective, single-blind, randomized study was to compare the efficacy of the
      combination of celecoxib and pregabalin and celecoxib only monotherapy for treatment of
      chronic low-back pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety of the association of celecoxib [a selective cyclooxygenase-2 (COX-2)
      inhibitor] and pregabalin (commonly used to control neuropathic pain), compared with
      monotherapy of each, were evaluated for the treatment of chronic low-back pain, a condition
      known to be due to neuropathic as well as nociceptive pain mechanisms.

      We will compare the efficacy of the combination of a selective COX-2 inhibitor (celecoxib)
      and an antineuropathic drug, pregabalin, versus celecoxib only monotherapy, in the treatment
      of spinal stenosis.

      Each treatment lasted 8 weeks

      Primary outcome is mean pain reduction following different treatments regimes. Secondary
      outcomes are the changes of pain sensitivity, Oswestry disability index, adverse effects due
      to the treatments under study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Pain score for low back and lower leg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain sensitivity questionnaire (PSQ)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>Level of pain sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry disability index (ODI)</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>The self-completed questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spinal Stenosis Lumbar</condition>
  <arm_group>
    <arm_group_label>Pregabalin and COX-2 inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 75mg BID + Celecoxib 200mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COX-2 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 75mg</intervention_name>
    <description>Orally taken twice daily for 8 weeks</description>
    <arm_group_label>Pregabalin and COX-2 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex 200Mg Capsule</intervention_name>
    <description>Orally taken once daily for 8 weeks</description>
    <arm_group_label>COX-2 inhibitor</arm_group_label>
    <arm_group_label>Pregabalin and COX-2 inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spinal stenosis

        Exclusion Criteria:

          -  Koval grade &gt;=3

          -  Other musculoskeletal disorders which cause pain on other joint

          -  Bleeding risk or ulcer history

          -  Severe cardiovascular, pulmonary, renal, brain, liver dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ho-Joong Kim, M.D., Ph.D</last_name>
    <phone>+82317872300</phone>
    <email>oshjkim@gmail.com</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>June 29, 2018</last_update_submitted>
  <last_update_submitted_qc>June 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Ho-Joong Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pregabalin</keyword>
  <keyword>Selective COX-2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

